^
Association details:
| Biomarker: | MSI-H/dMMR |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Puyouheng (pucotenlimab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer
Excerpt:
...Confirmed MSI-H/dMMR status by the central laboratory; 5....
Trial ID:
Source:
Title:
Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors
Excerpt:
...1 in the Cohort 2 1.Advanced malignant solid tumors confirmed by histology or cytology and confirmed as msi-h or dMMR by the central laboratory designated by the sponsor....
Trial ID:
Less C2 evidence
Source:
Title:
Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study
Published date:
11/15/2023
Excerpt:
Overall, 100 patients with previously treated, advanced solid tumors centrally confirmed as dMMR or MSI-H received pucotenlimab at 200 mg every 3 weeks. The most common cancer type is colorectal cancer (n = 71)...For the biomarker analysis, responders are enriched in patients with mutations in the KMT2D gene. Pucotenlimab is an effective treatment option for previously treated advanced dMMR/MSI-H solid tumors...
DOI:
10.1016/j.xcrm.2023.101301
Trial ID:
Source:
Title:
Efficacy of HX008 in high microsatellite instability/mismatch repair–defificient (MSI-H/dMMR) solid tumors: Results from a multicenter phase II open-label study.
Published date:
05/19/2021
Excerpt:
The aim of this study is to identify the efficacy and safety of HX008, an anti-PD-1 monoclonal antibody, in patients with advanced MSI-H/dMMR solid tumors….The most common cancer types were colorectal cancer (N=74) and gastric cancer (N=10)….ORR and DCR for the 66 colorectal cancer patients were 50% (95%CI 37.43-62.57%) and 75.76% (95%CI 63.64-85.46%).
DOI:
10.1200/JCO.2021.39.15_suppl.2572
Trial ID:
